SCHEMBL2661397

SCHEMBL2661397

Cc1nn(C)cc1-c1c(F)ccc2c(N)c3c(nc12)CN(C1CCOC1)C3=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CREBBP Q92793 8/20 0.39
▸ BRD4 O60885 7/20 0.39
▸ FGFR1 P11362 2/20 0.38
▸ FGFR4 P22455 2/20 0.38
▸ SCN9A Q15858 2/20 0.33
▸ SCN10A Q9Y5Y9 1/20 0.33
▸ PIK3CA P42336 3/20 0.32
▸ FGFR2 P21802 1/20 0.32
▸ FGFR3 P22607 1/20 0.32
▸ GABRG2 P18507 1/20 0.31
▸ GABRB3 P28472 1/20 0.31
▸ GABRA5 P31644 1/20 0.31
▸ KCNH2 Q12809 1/20 0.31
▸ ATR Q13535 1/20 0.31
▸ ATRIP Q8WXE1 1/20 0.31
▸ PIK3CD O00329 2/20 0.31
▸ PIK3R1 P27986 1/20 0.31
▸ PIK3CG P48736 1/20 0.31
▸ ADORA2A P29274 1/20 0.30
▸ ADORA2B P29275 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2669506 1.00 CREBBP (0.39) CREBBPBRD4FGFR1FGFR4SCN9A
SCHEMBL2660129 0.81 SCN9A (0.35) SCN9ASCN10APIK3CAGABRG2GABRB3
SCHEMBL2660127 0.81 SCN9A (0.35) SCN9ASCN10APIK3CAGABRG2GABRB3
SCHEMBL2657245 0.81 SCN9A (0.35) SCN9ASCN10APIK3CAGABRG2GABRB3
SCHEMBL2656626 0.80 MTOR (0.36) SCN9APIK3CAGABRG2GABRB3ATR
SCHEMBL8109980 0.80 MTOR (0.36) SCN9APIK3CAGABRG2GABRB3ATR
SCHEMBL8104270 0.80 MTOR (0.36) SCN9APIK3CAGABRG2GABRB3ATR
SCHEMBL2661410 0.75 MEN1 (0.37) CREBBPBRD4FGFR1FGFR4PIK3CA
SCHEMBL2660496 0.71 GABRG2 (0.44) GABRG2GABRB3
SCHEMBL2669536 0.71 NPY1R (0.41) GABRG2GABRB3ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF CREBBP 2372/4885BRD4 1608/4885FGFR1 2218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback